Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FID-022
- Development stage
- Phase 1
- Lead developer
- Fulgent Pharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FID-022 is an investigational intravenous nanoencapsulated formulation of SN-38, the active metabolite of irinotecan. It uses Fulgent Pharma's polyethyloxazoline-based nano-drug delivery platform to encapsulate the topoisomerase I inhibitor. By stabilizing the DNA-topoisomerase I cleavage complex, SN-38 produces DNA damage and cytotoxicity in tumor cells. FID-022 is being evaluated as monotherapy in a first-in-human Phase 1 dose-escalation study in adults with advanced solid tumors. ([fulgentpharma.com](https://www.fulgentpharma.com/pipeline/fid-022))
- Other names
- FID022FID-022FID 022
02
Targets
TOP (DNA topoisomerases)
Beyond the preview
Go deeper on FID-022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FID-022.